systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2019.4.190574systhiper-594Research ArticleКАРДИОЛОГИЯCARDIOLOGYХарактер течения артериальной гипертонии при низкорениновом гиперальдостеронизмеThe nature of the course of arterial hypertension in low-renin hyperaldosteronismЧихладзеН. М.ChikhladzeN. M.ovella.cardio@mail.ruФГБУ «НМИЦ кардиологии»РоссияMyasnikov Institute of Clinical Cardiology, National Medical Research Center of CardiologyRussian Federation2019231220221642226Copyright © Чихладзе Н.М., 20222022Чихладзе Н.М.Chikhladze N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/594

В обзоре рассматривается характер течения артериальной гипертонии (АГ) при опухолевых и гиперпластических изменениях в коре надпочечников, приводящих к развитию низкоренинового гиперальдостеронизма. Проанализированы степень тяжести и характер течения АГ. Показано, что в большинстве случаев развивается высокая стабильная АГ, наблюдается резистентность к антигипертензивной терапии. Обращено внимание на особенности течения АГ: варианты кризового повышения артериального давления, а также случаи умеренно повышенного и даже нормального уровня артериального давления. Рассмотрены возможные патогенетические механизмы, обусловливающие особенности течения АГ. С учетом результатов проведенных исследований, включая собственные данные, обосновывается важность анализа индивидуальных особенностей течения заболевания для выбора лечебной тактики и уменьшения риска недиагностированных альдостером.

The review examines the nature of the course of arterial hypertension (AH) in case of tumor and hyperplastic changes in the adrenal cortex, leading to the development of low-renin hyperaldosteronism. The severity and nature of the course of AH were analyzed, it was shown that in most cases high stable hypertension develops, and resistance to multidrug antihypertensive therapy is observed. Attention is drawn to the features of the course of AH: options for hypertensive crisis, as well as cases of a moderately elevated and even normal level of blood pressure. Possible pathogenetic mechanisms that determine the characteristics of the course of AH are considered. Based on the results of the studies, including our own data, the importance of analyzing the individual characteristics of the course of the disease in order to select preferable methods of treatment and reduce the risk of undiagnosed aldosteromas is substantiated.

низкорениновый гиперальдостеронизмрезистентная артериальная гипертониягипертонические кризынормотонияlow-renin hyperaldosteronismresistant arterial hypertensionhypertensive crisesnormotensive patientsReferencesFunder J.W, Carey R.M, Mantero F et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889-916.Funder J.W, Carey R.M, Mantero F et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889-916.Чихладзе Н.М. Симптоматические (вторичные) артериальные гипертонии. Диагностика и лечение. Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. М.: МИА, 2018.Чихладзе Н.М. Симптоматические (вторичные) артериальные гипертонии. Диагностика и лечение. Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. М.: МИА, 2018.Conn J.W. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.Conn J.W. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.Baer L, Sommers S.C, Krakoff L.R et al. Pseudoprimary aldosteronism: an entity distinct from true primary aldosteronism. Circ Res 1970; 27 (Suppl. 1): 203-20.Baer L, Sommers S.C, Krakoff L.R et al. Pseudoprimary aldosteronism: an entity distinct from true primary aldosteronism. Circ Res 1970; 27 (Suppl. 1): 203-20.Pignatelli D, Falcao H, Coimara-Pixoto A, Cruz F. Unilateral adrenal hyperplasia. South Med J 1994; 87: 664-7.Pignatelli D, Falcao H, Coimara-Pixoto A, Cruz F. Unilateral adrenal hyperplasia. South Med J 1994; 87: 664-7.Omura M, Sasano H, Fujiwara T et al. Unique Cases of Unilateral Hyperaldosteronemia Due to Multiple Adrenocortical Micronodules, Which Can Only be Detected by Selective Adrenal Venous Sampling. Metabolism 2002; 51 (3): 350-5.Omura M, Sasano H, Fujiwara T et al. Unique Cases of Unilateral Hyperaldosteronemia Due to Multiple Adrenocortical Micronodules, Which Can Only be Detected by Selective Adrenal Venous Sampling. Metabolism 2002; 51 (3): 350-5.Stowasser M, Gartside M.G, Gordon R.D. A PCR-based method of sсreening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust NZJ 1997; 27: 685-90.Stowasser M, Gartside M.G, Gordon R.D. A PCR-based method of sсreening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust NZJ 1997; 27: 685-90.Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 9: 115-22.Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 9: 115-22.Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-18.Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-18.Ruilope L.M. Aldosterone, Hypertension, and cardiovascular disease. Hypertension 2008; 52: 207.Ruilope L.M. Aldosterone, Hypertension, and cardiovascular disease. Hypertension 2008; 52: 207.Knoz F.G, Burnett J.C, Kohan D.E et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Intern 1980; 17: 263-76.Knoz F.G, Burnett J.C, Kohan D.E et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Intern 1980; 17: 263-76.Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. М.: Медицина, 1984.Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. М.: Медицина, 1984.Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.Monticone S, Burrello J, Tizzani D et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-20.Monticone S, Burrello J, Tizzani D et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-20.Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region. J Hum Hypertens 2003; 17: 349-52.Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region. J Hum Hypertens 2003; 17: 349-52.Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15-9.Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15-9.Cushman W.C, Ford C.E, Cutler J.A et al; for the ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.Cushman W.C, Ford C.E, Cutler J.A et al; for the ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.Calhoun D.A. Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1 (5): 1039-45.Calhoun D.A. Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1 (5): 1039-45.Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371 (9628): 1921-6.Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371 (9628): 1921-6.Чихладзе Н.М., Бронштейн М.Э., Казеев К.Н., Арабидзе Г.Г. Кризовое течение артериальной гипертонии у больных с первичным гиперальдостеронизмом. Кардиология. 1989; 11: 95-9.Чихладзе Н.М., Бронштейн М.Э., Казеев К.Н., Арабидзе Г.Г. Кризовое течение артериальной гипертонии у больных с первичным гиперальдостеронизмом. Кардиология. 1989; 11: 95-9.Stowasser M, Bachmann A.W, Huggard P.R et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160-6.Stowasser M, Bachmann A.W, Huggard P.R et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160-6.Mulatero P, Tizzani D, Viola A et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58 (5): 797-803.Mulatero P, Tizzani D, Viola A et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58 (5): 797-803.Ito Y, Takeda R, Karashima S et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102.Ito Y, Takeda R, Karashima S et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102.Moradi S, Shafiepour M, Amirbaigloo A. A woman with normotensive primary hyperaldosteronism. Acta Medica Iranica 2016; 54 (2): 156-8.Moradi S, Shafiepour M, Amirbaigloo A. A woman with normotensive primary hyperaldosteronism. Acta Medica Iranica 2016; 54 (2): 156-8.Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-95.Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-95.Médeau V, Moreau F, Trinquart L et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol 2008; 69 (1): 20-8.Médeau V, Moreau F, Trinquart L et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol 2008; 69 (1): 20-8.Vantyghem M-C, Ronci N, Provost F et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141: 279-85.Vantyghem M-C, Ronci N, Provost F et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141: 279-85.Nishimiya T, Kikuchi K, Oimatsu H et al. A case of normotensive primary aldosteronism - comparison with 13 previously experienced cases with hypertension. Endocrinol Jpn 1984; 31 (2): 159-64.Nishimiya T, Kikuchi K, Oimatsu H et al. A case of normotensive primary aldosteronism - comparison with 13 previously experienced cases with hypertension. Endocrinol Jpn 1984; 31 (2): 159-64.Rossi G.P. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res 2011; 34: 43-6.Rossi G.P. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res 2011; 34: 43-6.

The authors declare that there are no conflicts of interest present.